Press Releases July 6, 2026 04:30 PM

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies releases half-year liquidity contract report with ODDO BHF

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
DBVT

DBV Technologies has issued its half-year report detailing the liquidity contract activities with ODDO BHF, covering transactions and asset holdings from January to June 2026. The liquidity contract supports trading in DBV Technologies shares listed both on Euronext Paris and Nasdaq.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBVT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The liquidity contract with ODDO BHF shows significant trading volume with over 2.7 million shares purchased and 2.6 million sold in the first half of 2026.
  • The number of DBV Technologies shares held under the liquidity account increased from 74,580 at year-end 2025 to 146,321 by June 30, 2026, indicating enhanced liquidity support.
  • DBV Technologies continues its focus on developing VIASKIN® patch technology for food allergy treatments, with ongoing clinical trials targeting children and toddlers.
  • Sectors impacted include biopharmaceuticals, healthcare, and allergy treatment markets, as well as equity markets due to the stock's dual listing and liquidity arrangements.

AMF Regulated Information
Châtillon, France, July 6, 2026

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF relating to DBV Technologies shares (the “Liquidity Contract”).

The Liquidity Contract is implemented in accordance with AMF Decision No. 2021-01 of June 22, 2021 on liquidity contracts on equity securities accepted as a market practice.

When the Liquidity Contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:

  • 41,159 DBV Technologies shares,
  • € 432,367.25.

It is reminded that, as of December 31, 2025, the following assets appeared on the liquidity account:

  • 74,580 DBV Technologies shares,
  • € 527,891.63.

As of June 30, 2026, the following assets appeared on the liquidity account:

  • 146,321 DBV Technologies shares,
  • € 396,088.22.

Over the period from January 1, 2026 to June 30, 2026, the following transactions were executed:

  • 1,989 buy transactions,
  • 2,012 sales transactions.

Over this same period, the volumes traded represented:

  • 2,707,915 shares and € 8,836,273.65 on purchases,
  • 2,636,174 shares and € 8,704,457.81 on sales.

Details of the transactions executed under the Liquidity Contract are provided in the appendix to this press release.

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Investor Contact
Jonathan Neely
DBV Technologies
[email protected]

Media Contact
Brett Whelan
DBV Technologies
[email protected]

Appendix - Details of transactions executed under the Liquidity Contract
Period from January 1, 2026 to June 30, 2026

The data below present, for each trading day, the number of transactions, traded volumes and corresponding amounts for purchases and sales.

DatePurchasesSales Number of transactionsNumber of sharesAmount (€)Number of transactionsNumber of sharesAmount (€)01/02/2026127,50024,637.49115,00016,640.0601/05/20261912,60038,180.0011,0003,325.0001/06/20261310,60031,799.0011,0003,095.0001/07/202624,80014,400.0075,00015,225.0001/08/20262235,000107,505.541320,00062,091.0101/09/20261415,00044,599.002128,00084,481.9301/12/20263027,09382,327.261430,00092,237.5001/13/20262527,90785,572.741012,50038,862.5001/14/20262220,75061,520.001622,50067,537.2501/15/20263947,500145,000.003042,129130,148.7101/16/202612,5007,950.003560,000197,900.0001/19/20263554,146198,418.084569,294261,747.0401/20/20264863,604229,516.922650,000182,062.5001/21/20261830,683110,939.603252,500193,212.5001/22/20261733,817128,060.402337,500142,661.1801/23/2026000.001829,206117,895.4601/26/20263635,000143,000.0012,50010,475.0001/27/20261512,50048,625.0097,50029,675.0001/28/2026815,00061,150.001020,33083,482.7001/29/20261115,00060,025.00000.0001/30/20261415,22459,070.6025,00019,700.0002/02/20262739,776144,796.021317,50065,475.0002/03/2026410,00037,450.00910,00038,362.5002/04/20261215,00060,025.002127,170110,792.3002/05/20261717,50067,175.0043,56913,976.1102/06/20262236,000129,240.0023,00010,920.0002/09/2026712,00043,920.002236,000134,140.0002/10/202668,00030,400.001936,000143,660.0002/11/20261236,000138,360.0098,75034,400.0002/12/202688,00029,800.00511,25042,640.0002/13/2026911,61442,507.24412,00044,680.0002/16/20261735,386124,328.11000.0002/17/202614,00013,600.0038,00027,720.0002/18/202614,00013,840.00412,00042,100.0002/19/2026516,00055,560.001012,00042,280.0002/20/202628,00028,480.00616,00058,040.0002/23/2026312,00042,920.00916,00058,040.0002/24/202674,00014,240.00620,00073,800.0002/25/2026812,00046,280.00716,00062,440.0002/26/20261020,00075,040.00000.0002/27/20262128,000103,220.00716,00059,840.0003/02/20261512,00141,843.501716,00159,443.5003/03/2026000.0014,00015,360.0003/04/202628,00029,520.00000.0003/05/2026916,00160,803.901124,00194,803.9003/06/2026412,00143,883.80113.8003/09/2026912,00044,160.001732,000123,480.0003/10/20261311,34945,342.04816,00065,520.0003/11/20261520,65179,977.96000.0003/12/20262336,000131,600.00000.0003/13/2026712,00042,720.001520,00073,200.0003/16/202658,49830,003.08208,00028,760.0003/17/20261111,50239,996.9224,00013,960.0003/18/2026620,00068,160.00000.0003/19/2026148,00026,480.0068,00026,920.0003/20/202658,00027,080.001512,00041,320.0003/23/2026712,18640,446.36720,00067,880.0003/24/2026612,00040,520.0044,00013,740.0003/25/2026512,00041,720.001824,00084,440.0003/26/202698,00027,440.00716,00056,240.0003/27/202658,17528,885.501424,00087,080.0003/30/202647,82527,274.5034,00014,200.0003/31/20261512,00041,920.00920,00072,000.0004/01/202614,00014,440.00816,00059,240.0004/02/20261428,000100,280.0024,31815,733.4204/07/20261112,00042,616.0014,00014,400.0004/08/2026312,00043,320.001317,22164,006.5404/09/202694,00014,440.0044,00014,560.0004/10/20261836,000127,768.002226,77995,220.1104/13/20261424,00082,600.002724,00084,584.0004/14/2026000.00624,00089,872.0004/15/20261016,00059,720.0014,00015,560.0004/16/20261120,00071,200.0013,12811,417.2004/17/202614,00014,240.00715,87256,974.0804/20/2026616,00057,960.00516,00059,240.0004/21/202648,00127,883.6154,00114,443.6104/22/2026712,00040,520.00104,18014,387.2004/23/202628,00026,520.0048,00026,800.0004/24/202628,00026,680.00712,00040,480.0004/27/2026000.00411,82041,060.8004/28/202634,00014,040.00512,00042,680.0004/29/202664,00114,243.6134,00114,603.6104/30/2026113.5824,00114,563.5805/04/20262244,000149,592.0058,00027,720.0005/05/202614,00013,640.00820,00069,200.0005/06/202638,00027,880.001020,00070,912.0005/07/20261312,00040,920.0078,00028,160.0005/08/202614,00013,440.00167,33925,198.1605/11/202655,48618,587.26919,66168,433.8405/12/2026820,00070,040.002220,00070,160.0005/13/2026710,51535,856.2714,00014,160.0005/14/2026612,00140,683.4373,83012,983.7405/15/2026113.3958,17227,775.0805/18/20261816,29153,868.6624,00013,360.0005/19/2026711,70937,741.6724,00012,960.0005/20/202638,00025,680.0048,00025,920.0005/21/20263539,461125,963.854532,765104,996.5805/22/20263641,465134,564.982438,422125,502.4305/25/2026113.212811,00136,099.8105/26/20265157,996187,226.423729,34794,640.6305/27/20262729,54094,371.933929,54094,862.1705/28/20262934,900112,561.122636,949119,709.0905/29/20264534,636113,709.875054,317180,114.1006/01/2026612,00038,720.0014,00012,960.0006/02/20264044,471139,502.6789,32329,520.4606/03/20263740,689124,961.603840,689125,612.6206/04/20263240,778121,898.755544,124132,529.4006/05/20263668,118198,415.115337,330108,954.1806/08/202635,09114,251.16412,00034,320.0006/09/20264146,255130,630.615450,830150,563.4506/10/20263149,047133,277.033449,725135,810.6206/11/20263028,39579,438.652234,58197,055.9106/12/202614081,148.115072,598212,397.8706/15/202656,87020,730.164665,313202,736.1706/16/20264461,048191,276.983640,712129,424.1806/17/20263043,656126,621.373236,538106,286.2406/18/20266171,957206,327.052742,208122,773.1706/19/20262342,017116,161.552852,995147,717.8006/22/20265346,656131,179.025042,257119,548.5906/23/20265161,396174,002.753562,760178,816.4606/24/20264555,846159,697.494654,770157,555.1706/25/20265662,148177,937.744458,952169,542.2406/26/20261834,56295,882.815069,263194,862.2706/29/20266257,608169,404.323657,823170,500.0206/30/202653123,205326,744.3111972,518198,164.77Total1,9892,707,9158,836,273.652,0122,636,1748,704,457.81

Source: monthly declarations and ODDO BHF execution statements for DBV Technologies for the period from January 1 to June 30, 2026.

Attachment

  • PDF Version

Risks

  • Liquidity contract performance depends on ongoing market conditions, which may influence share price volatility and trading volumes, impacting investor confidence.
  • DBV Technologies' late-stage biopharmaceutical development status entails risks related to clinical trial outcomes and regulatory approvals, which can affect its market valuation.
  • Dependence on the success of the VIASKIN® patch technology to address food allergies introduces product development and commercial risks tied to competitive and regulatory environments.

More from Press Releases

Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Decrease in June 2026 of 5.1% Compared to 2025 Jul 6, 2026 Exyn Technologies Reports First Quarter 2026 Financial Results Successfully Completed Initial Public Offering, and Continued Expansion of ExynAI Across Commercial and Government Markets Jul 6, 2026 Cloudastructure Strengthens Balance Sheet with Elimination of Variable Conversion Debt Feature and Provides Update on First Quarter 2026 Filing Jul 6, 2026 Postal Realty Enhances Capital Structure with Credit Facility Recast Jul 6, 2026 Dorchester Minerals, L.P. Announces Agreement to Acquire Mineral and Royalty Interests Jul 6, 2026